COMPANY PROFILE

Novacea

Explore full profile

San Francisco, United StatesFounded 2001Biotech & Life Sciences

Valuation $100–250M Last recorded · 2004

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

At a glance

Status: Acquired
Founded: 2001
Headquarters: San Francisco, United States
Employees: 13
Open positions: None listed
Dealroom signal: 18.0/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: LinkedIn

Founder mafia, market maps, research and news connected to this company by Dealroom

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Feb 2009	$0	—	Transcept Pharmaceuticals	↗
SERIES COther financing	Jan 2004	$35M	$140M	NEA · Versant Ventures · Domain Associates · Apax Partners	—

Novacea team growth

Novacea's team grew 8.3% over the past year.

1-year team growth+8.3%

Summary metrics are public; monthly history is available with a demoCompare with peers →

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
XIXilisDeveloping next generation technologies for precision medicine and drug discovery	Durham, United States	Operational
PUPulmobioticsDiscovers and develops novel treatments and vaccines for respiratory diseases	Barcelona, Spain	Operational
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational